MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/oby.70125

Медицинская библиотека · Obesity (Silver Spring, Md.) · 2026

Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.

Argente Jesús, Haqq Andrea M, Schorfheide Jan Luca, Touchot Nicolas, Huber Caroline, Wiedemann Urs, Pomeroy Jeremy, Phase 3 BBS Trial Investigators

СтатьяКлиническое исследование III фазыСравнительное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet-Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS).

METHODS

Patients with BBS ≥ 6 years of age (n = 29) treated with setmelanotide for 52 weeks in a phase 3 trial (NCT03746522) and a propensity-score matched external control cohort (n = 58) from CRIBBS were included. Responder rate at week 52 was defined as ≥ 0.3-point decrease in BMI z-score (patients ≤ 18 years) or ≥ 10% body weight reduction (adults). Secondary outcomes included changes in BMI, BMI z-score, and body weight.

RESULTS

A significantly greater proportion of patients treated with setmelanotide met the primary endpoint compared with control patients (58.6% vs. 6.9%; p < 0.001). In pediatric patients, 71.4% achieved the primary endpoint vs. 10.7% of controls (p < 0.001); in adults, corresponding numbers were 46.7% vs. 3.3% (p = 0.001). Secondary outcomes demonstrated consistent benefits of setmelanotide treatment. Sensitivity analysis using inverse probability of treatment weighting confirmed these findings.

CONCLUSIONS

This indirect comparison provides additional strong evidence that setmelanotide significantly improves weight outcomes in patients with BBS. These findings further support its clinical benefit over 52 weeks in managing obesity associated with BBS.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03746522.

Для цитирования: Argente Jesús, Haqq Andrea M, Schorfheide Jan Luca, Touchot Nicolas, Huber Caroline, Wiedemann Urs, Pomeroy Jeremy, Phase 3 BBS Trial Investigators. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.. Obesity (Silver Spring, Md.). 2026. DOI: 10.1002/oby.70125.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.